IRIDEX (NASDAQ:IRIX) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of IRIDEX (NASDAQ:IRIX) in a research report issued to clients and investors on Sunday. The brokerage set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Price Performance

Shares of IRIX opened at $1.76 on Friday. The company has a quick ratio of 0.86, a current ratio of 1.54 and a debt-to-equity ratio of 0.55. The stock has a market cap of $29.28 million, a PE ratio of -2.63 and a beta of 0.80. IRIDEX has a 12-month low of $1.27 and a 12-month high of $3.65. The business has a 50-day simple moving average of $1.67 and a two-hundred day simple moving average of $2.01.

IRIDEX (NASDAQ:IRIX) last released its quarterly earnings data on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share (EPS) for the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. The firm had revenue of $11.58 million during the quarter. During the same period in the prior year, the company earned ($0.11) earnings per share.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.